BBIO Q2 2021 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

$14B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$54M

Gross Profit

$54M99.8% margin

Operating Income

-$94M-174.0% margin

Net Income

-$96M-178.3% margin

EPS (Diluted)

$-0.66

QoQ Revenue Growth

+11593.5%

Cash Flow

Operating Cash Flow

-$92M

Free Cash Flow

-$94M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$1.5B

Stockholders' Equity

-$464M

Cash & Equivalents

$379M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$54M	$0	—
Gross Profit	$54M	$0	—
Operating Income	-$94M	-$125M	+24.5%
Net Income	-$96M	-$121M	+20.4%

Revenue Segments

Product

$987,000100%